Currently Viewing:
ISPOR 2019
Panelists Discuss the Potential and Pitfalls of Disruption in Healthcare
May 20, 2019
Currently Reading
Trends in Value That Dr Daniel Mullins Expects to See in Coming Years
May 21, 2019
The Imperfect QALY: How It's Used Depends on Where You Enter Value Discussions
May 21, 2019
Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease
May 22, 2019
Panelists Debate the Role of ICER: Useful Overseer of Prices, or Oppressor of Choice?
May 22, 2019
Bringing Financial Theory Into the Value Equation of Future Cutting-Edge Therapies
May 22, 2019
Dr Devin Incerti Outlines Best Practices for Approaching Value Assessment
May 22, 2019
Biosimilar Experts Give Highlights of US Uptake Issues
May 23, 2019
Dr Nicholas Robert Explains the Benefits, Challenges of Using RWE for Measuring Clinical End Points
May 23, 2019
Dr Eleanor Perfetto Outlines Criticisms of the QALY
May 23, 2019
New Therapies Offer Possible Cures but Pose Affordability Challenges
May 23, 2019
Fremanezumab Cost Effective for Both Types of Migraine, Researchers Say
May 27, 2019
Dr Jon Campbell on Benefits of Using MCDA in Value Assessment
June 03, 2019
Dr Nicholas Robert Explains the Need to Standardize Use of RWE for Measuring Clinical End Points
June 23, 2019
Dr Devin Incerti: Use Value Assessments to Maximize the Well-Being of a Population
July 14, 2019
Dr Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data
July 16, 2019
Dr Eleanor Perfetto on Ways to Improve Transparency, Education Around Value Assessment
July 23, 2019
Dr Nicholas Robert on Lag Time Between Drug Approval, Availability of the Drug in EMRs
July 29, 2019
Dr Nicholas Robert: Lag Time Between a Drug Approval, Availability in EMRs Can Impact Patient Care
August 10, 2019
Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs
August 22, 2019

Trends in Value That Dr Daniel Mullins Expects to See in Coming Years

Daniel Mullins, PhD, discusses what trends he expects to see in coming years regarding value in healthcare.


Daniel Mullins, PhD, chair, Pharmaceutical Health Services Research, School oh Pharmacy, University of Maryland, discusses what trends he expects to see in coming years regarding value in healthcare.

Transcript

What are some trends you expect to see in coming years in regard to value in healthcare?

There are a couple of trends that I predict, some of which are perhaps futuristic and some of which really might happen in the next year. One trend that I hope we’ll see is that insurance companies will really include patients and the public in their coverage and decision-making bodies, like a pharmacy and therapeutics committee. Only when there’s a seat at the table for patients will we have the patient voice involved in coverage decisions. Another trend is the use of patient preferences in a really meaningful way that will really drive healthcare, and I think this is not just in real-world clinical settings, but I think what’s happening at the FDA now is really exciting and that too will drive the future of healthcare.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up